Summary Safety Review - GARDASIL (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) - Assessing General Safety with a Focus on Autoimmune and Cardiovascular Diseases (English, HTML)

View metadata and access the original English HTML file: Summary Safety Review - GARDASIL (Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) - Assessing General Safety with a Focus on Autoimmune and Cardiovascular Diseases.

Format

HTML

Access

file-only

Publisher-reported update

2024-05-09

The safety of all vaccines, including Gardasil, is under continuous monitoring by Health Canada and the Public Health Agency of Canada. The safety of Gardasil was reassessed as part of this monitoring and when cases of side effects after vaccination with Gardasil were reported in early 2015. These side effects included diseases where the body's own defence system attacks itself (autoimmune diseases), such as rheumatoid arthritis and multiple sclerosis, and diseases affecting the heart and blood vessels (cardiovascular diseases), such as low blood pressure and blood clots.

Access original file